<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The rates of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, <z:hpo ids='HP_0001513'>obesity</z:hpo>, and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) continue to increase at epidemic proportions </plain></SENT>
<SENT sid="1" pm="."><plain>It has become clear that these <z:mp ids='MP_0002054'>disease states</z:mp> are not independent but are frequently interrelated </plain></SENT>
<SENT sid="2" pm="."><plain>By addressing conditions such as <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, stress <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo>, and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, with its micro- and macrovascular complications, a specific treatment strategy can be developed </plain></SENT>
<SENT sid="3" pm="."><plain>These conditions can be addressed by early identification of patients at high risk for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, prompt and aggressive treatment of their <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, recognition of the pleiotropic and synergistic benefits of certain antidiabetes agents on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, and thus, avoiding potential complications including <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> and <z:mp ids='MP_0005456'>weight gain</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Incretin-based therapies, which include glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 (GLP-1) receptor <z:chebi fb="4" ids="48705">agonists</z:chebi> and dipeptidyl peptidase-IV (DPP-IV) inhibitors, have the potential to alter the course of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> complications </plain></SENT>
<SENT sid="5" pm="."><plain>Advantages of these therapies include <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent enhancement of insulin secretion, infrequent instances of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, <z:hpo ids='HP_0001824'>weight loss</z:hpo> with GLP-1 receptor <z:chebi fb="4" ids="48705">agonists</z:chebi>, weight maintenance with DPP-IV inhibitors, decreased blood pressure, improvements in <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e>, and potential beneficial effects on CV function </plain></SENT>
</text></document>